Very soft, 100% TPU combines 65A performance with chemical resistance, thin-wall processability, and manufacturing versatility

Collaboration expands access to Lunit's AI-powered pathology platform by combining it with Discovery Life Sciences' global biospecimen and specialty laboratory capabilities, enabling standardized tissue insights for biomarker research and drug development

A redesigned patient experience drives engagement from prevention through survivorship, while chart-aware risk intelligence surfaces guideline-based recommendations in EHR workflows

104 IPF patients enrolled in US and South Korea as global Phase 2 trial progresses toward completion

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1. Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting

Heraeus Medical has expanded its portfolio with the strategic business area ‘resorbable biomaterials’. With this step, the company is continuing its global growth strategy and strengthens its research and development activities for orthopaedic and trauma care

Collaboration with AAV-specialist CDMO will support scalable production of EPY201 for focal refractory epilepsy affecting 10 million people

Molecular Instruments® (MI), founded by the inventor of HCR™ technology, today announced the availability of HCR™ Gold IF on Biocare Medical’s ONCORE Pro X, a fully open automated slide staining system for research laboratories. Powered by the HCR™ HiFi Encoder, HCR™ Gold IF lets researchers build multiplex immunofluorescence assays with...

Brings Together Oncology, Inflammation and Research Data. Science Teams to Foster Scientific Collaboration – – One of Three Foster City Projects Supporting Gilead’s $32 Billion U.S. Investment and 3,000 High-Quality Domestic Jobs.

The Comprehensive Liver Function Test, a self-collection blood test measuring 20+ liver health markers for a disease that affects roughly one third of U.S. adults but remains undiagnosed in the majority of cases

Peptides are short chains of amino acids that laboratories use as raw material across a wide range of drug research

GV101, is a novel, highly selective ROCK2 inhibitor, yielded an 86.2% best overall response rate (bORR) at 400 mg and a 67.9% bORR at 200 mg at 24 weeks in chronic Graft versus Host Disease (cGvHD) patients who had failed at least two prior lines of therapy